<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03624946</url>
  </required_header>
  <id_info>
    <org_study_id>ZK-001</org_study_id>
    <nct_id>NCT03624946</nct_id>
  </id_info>
  <brief_title>Study in Healthy Volunteers Evaluating Safety and Pharmacokinetics of Zika Virus Immune Globulin (ZIKV-IG)</brief_title>
  <official_title>Safety and Pharmacokinetic Evaluation of Zika Virus Immune Globulin in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emergent BioSolutions</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emergent BioSolutions</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Currently, there are no licensed therapeutics against Zika virus infection. Due to this unmet
      medical need, Zika Virus Immune Globulin (ZIKV-IG) is being developed as a therapeutic
      intervention against Zika virus infection. In this first-in-human study, evaluation of
      ZIKV-IG safety and pharmacokinetics (absorption, metabolism and excretion) will be conducted
      in healthy adult volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be evaluating safety and pharmacokinetics (PK) of one dose level of ZIKV-IG
      (50 mL) in healthy adult volunteers. The study is a single-center, double-blind, randomized
      and placebo-controlled design. The primary objective is to assess safety of intravenously
      (IV) administered ZIKV-IG, while the secondary objective is to determine the PK profile of
      ZIKV-IG in healthy adult volunteers.

      There will be a total of 30 subjects enrolled into the study; dosing of the first six
      subjects will be staggered over three separate days, wherein two subjects per day will be
      randomized 1:1 to either receive 50 mL of placebo IV or 50 mL of ZIKV-IG IV (the total amount
      of gamma immune globulin [IgG] protein from a single 50mL dose is 4.65g). After the first six
      subjects are dosed, the remaining 24 subjects will be randomized 2:1 to receive either
      ZIKV-IG or placebo. A safety monitoring committee will review safety data (collected up to 3
      days post-dosing) of the first 12 dosed subjects prior to dosing of the remaining 18
      subjects. Overall, there will be 19 subjects randomized to receive ZIKV-IG and 11 subjects
      randomized to receive placebo on Day 1. On Day 1 (post-dose at 1 hour, 3 hours, 8 hours) and
      Day 2, safety and PK assessments will be conducted while the subjects are in the Phase 1
      clinic. After the discharge on Day 2, the subjects will come back to the clinic for safety
      and PK assessments on Days 3, 4, 6, 8, 10, 12, 15, 22, 29, 43, 57 and 85. Total study
      duration for each subject will be up to 4 months (from screening to Day 85).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 27, 2018</start_date>
  <completion_date type="Actual">March 6, 2019</completion_date>
  <primary_completion_date type="Actual">March 6, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and Severity of Adverse Events.</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Number and severity of adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Zika Virus Immune Globulin (ZIKV-IG) Maximum Concentration (Cmax)</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Maximum observed serum concentration of Zika Virus Immune Globulin (ZIKV-IG)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Zika Virus Immune Globulin (ZIKV-IG) Time to Maximum Concentration (Tmax)</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Time at which maximum serum concentration of Zika Virus Immune Globulin (ZIKV-IG) occurs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Zika Virus Immune Globulin (ZIKV-IG) Area Under the Curve Up to Last Quantifiable Concentration (AUC0-t)</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Area under the concentration-time curve from time 0 to the last quantifiable serum Zika Virus Immune Globulin (ZIKV-IG) concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Zika Virus Immune Globulin (ZIKV-IG) Area Under the Curve Extrapolated to Infinity (AUC0-inf)</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Area under the concentration-time curve from time 0 to the last quantifiable serum Zika Virus Immune Globulin (ZIKV-IG) concentration, plus the area extrapolated to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Zika Virus Immune Globulin (ZIKV-IG) Clearance (CL)</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Total body clearance of Zika Virus Immune Globulin (ZIKV-IG) following IV administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Zika Virus Immune Globulin (ZIKV-IG) Half-Life (t1/2)</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Apparent first order terminal elimination half-life of Zika Virus Immune Globulin (ZIKV-IG).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Zika Virus Immune Globulin (ZIKV-IG) Volume of Distribution (Vz)</measure>
    <time_frame>Up to Day 85</time_frame>
    <description>Volume of distribution of Zika Virus Immune Globulin (ZIKV-IG) following IV administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Zika Virus Infection</condition>
  <condition>Zika Virus Disease</condition>
  <arm_group>
    <arm_group_label>Zika Virus Immune Globulin (ZIKV-IG)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of 50 mL Zika Virus Immune Globulin (ZIKV-IG) will be administered intravenously over 33 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Saline Solution)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single dose of 50 mL placebo will be administered intravenously over 33 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Zika Virus Immune Globulin (ZIKV-IG)</intervention_name>
    <description>Zika Virus Immune Globulin (ZIKV-IG) is a human immune globulin preparation containing neutralizing antibodies to Zika virus.</description>
    <arm_group_label>Zika Virus Immune Globulin (ZIKV-IG)</arm_group_label>
    <other_name>Anti-Zika Immune Globulin (Human)</other_name>
    <other_name>NP-024</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo is a normal saline solution (0.9% sodium chloride).</description>
    <arm_group_label>Placebo (Saline Solution)</arm_group_label>
    <other_name>Saline solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent voluntarily signed by subject.

          2. Age: 18-55 years of age.

          3. Blood type O+ or O-.

          4. Body mass index (BMI) of 18-30.

               -  Note: minimum body weight of 50 kg.

          5. For female subjects (with male partners) that are not surgically sterilized (e.g., did
             not undergo hysterectomy, bilateral oophorectomy or tubal ligation), use of an
             effective method of contraception throughout the trial including:

               -  Using hormonal contraception (oral, injectable or implant) continuously for 3
                  months prior to screening and willing to continue to use hormonal contraception
                  throughout the entire trial.

               -  Intrauterine device (IUD) inserted at least 1 month prior to screening.

               -  Double barrier type of birth control measure (e.g., condoms, diaphragms, cervical
                  sponge with spermicide).

               -  True abstinence.

               -  For female subjects who are post-menopausal, documented follicle- stimulating
                  hormone (FSH) â‰¥40 milli-international units per milliliter (mIU/mL) must be
                  obtained. If the FSH is &lt;40 mIU/mL, the subject must agree to use an acceptable
                  form of contraception (see above).

               -  Females of childbearing potential without male sexual partners must be willing to
                  maintain their sexual status as it is throughout the study.

          6. For male subjects that have not had a vasectomy, use of a condom with spermicide or
             true abstinence for the duration of the study. Note: female partners (that are of
             childbearing potential) of male study subjects (that have not had a vasectomy) should
             use one of the effective contraception methods (eg, hormonal contraception, IUD or
             barrier type). Also, male subjects must not donate sperm for the duration of the
             study.

               -  Males without female sexual partners must be willing to maintain their sexual
                  status as it is throughout the study.

          7. Healthy as determined by principal investigator or a qualified designate based on
             medical history, physical exam, vital signs, urinalysis, blood chemistry and
             hematology test results at screening.

        Exclusion Criteria:

          1. Use of any investigational product within the past 30 days.

          2. Use of any investigational product during the study.

          3. Individuals with blood type A, B or AB.

          4. Recipient of any blood product within the past 12 months.

          5. Plasma donation within 7 days or significant blood loss or blood donation within 56
             days of baseline.

          6. Blood donation at any time during the study.

          7. Females with a hemoglobin level â‰¤120 g/L.

          8. Males with a hemoglobin level &lt;130 g/L.

          9. History of hypersensitivity to blood or plasma products.

         10. History of allergy to latex or rubber.

         11. History of immunoglobulin A (IgA) deficiency.

         12. History of hypercoagulable conditions (e.g., deep vein thrombosis or pulmonary
             embolism).

         13. History of myocardial infarction.

         14. History of stroke.

         15. History of renal impairment/failure.

         16. Currently pregnant or lactating or planning to become pregnant during the study.

         17. History of flavivirus infection [ZIKV, dengue virus (DENV), West Nile virus (WNV),
             Japanese encephalitis virus (JEV), yellow fever virus (YFV)] or vaccination with
             licensed or investigational flavivirus vaccine.

         18. Plans to travel to an area with active flavivirus (e.g., ZIKV and/or DENV)
             transmission during the study (and up to 10 months after the study drug
             administration) or has returned from an endemic area with these diseases within 30
             days of screening.

         19. Positive nucleic acid test (NAT) or serology for ZIKV or positive serology for WNV or
             DENV.

         20. Positive serology test (at screening) for human immunodeficiency virus 1 and 2 (HIV),
             hepatitis C virus (HCV); positive test for hepatitis B virus (HBV) as determined by
             HBsAg.

         21. History of chronic or acute severe neurologic condition (e.g., diagnosis of
             Guillain-Barre syndrome, epilepsy, Bell's palsy, meningitis or disease with any focal
             neurologic deficits).

         22. Heavy smokers (â‰¥15cigarettes a day) or electronic cigarette use.

         23. History of, or suspected substance abuse problem (including alcohol).

         24. Failure of drug (urine) test at screening or baseline.

         25. Failure of alcohol (breath) test at screening or baseline.

         26. Receipt of a live vaccine within 28 days prior to screening or anticipated receipt of
             a live vaccine during the study period.

         27. Individuals with planned surgical procedures that will occur during the study.

         28. An opinion of the investigator that it would be unwise to allow participation of the
             subject in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vadim Dreyzin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Syneos Health</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael McDonnell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Syneos Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Syneos Health, Early Phase</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5V 2T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 7, 2018</study_first_submitted>
  <study_first_submitted_qc>August 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2018</study_first_posted>
  <results_first_submitted>June 25, 2020</results_first_submitted>
  <results_first_submitted_qc>June 25, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 13, 2020</results_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Zika virus</keyword>
  <keyword>Human immune globulin</keyword>
  <keyword>Hyperimmune</keyword>
  <keyword>Polyclonal antibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zika Virus Infection</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 5, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT03624946/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan: SAP v1.0</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 18, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT03624946/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan: SAP Amendment 1</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT03624946/SAP_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan: SAP Amendment 2</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 28, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/46/NCT03624946/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Zika Virus Immune Globulin (ZIKV-IG)</title>
          <description>Single dose of 50 mL Zika Virus Immune Globulin (ZIKV-IG) containing 4.65g of gamma immune globulin (IgG) protein will be administered intravenously over 33 minutes.
Zika Virus Immune Globulin (ZIKV-IG): Zika Virus Immune Globulin (ZIKV-IG) is a human immune globulin preparation containing neutralizing antibodies to Zika virus.</description>
        </group>
        <group group_id="P2">
          <title>Placebo (Saline Solution)</title>
          <description>Single dose of 50 mL placebo will be administered intravenously over 33 minutes.
Placebo: Placebo is a normal saline solution (0.9% sodium chloride).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Zika Virus Immune Globulin (ZIKV-IG)</title>
          <description>Single dose of 50 mL Zika Virus Immune Globulin (ZIKV-IG) will be administered intravenously over 33 minutes.
Zika Virus Immune Globulin (ZIKV-IG): Zika Virus Immune Globulin (ZIKV-IG) is a human immune globulin preparation containing neutralizing antibodies to Zika virus.</description>
        </group>
        <group group_id="B2">
          <title>Placebo (Saline Solution)</title>
          <description>Single dose of 50 mL placebo will be administered intravenously over 33 minutes.
Placebo: Placebo is a normal saline solution (0.9% sodium chloride).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" lower_limit="21" upper_limit="52"/>
                    <measurement group_id="B2" value="30" lower_limit="23" upper_limit="55"/>
                    <measurement group_id="B3" value="33.5" lower_limit="21" upper_limit="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number and Severity of Adverse Events.</title>
        <description>Number and severity of adverse events.</description>
        <time_frame>Up to Day 85</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Zika Virus Immune Globulin (ZIKV-IG)</title>
            <description>Single dose of 50 mL Zika Virus Immune Globulin (ZIKV-IG) will be administered intravenously over 33 minutes.
Zika Virus Immune Globulin (ZIKV-IG): Zika Virus Immune Globulin (ZIKV-IG) is a human immune globulin preparation containing neutralizing antibodies to Zika virus.</description>
          </group>
          <group group_id="O2">
            <title>Placebo (Saline Solution)</title>
            <description>Single dose of 50 mL placebo will be administered intravenously over 33 minutes.
Placebo: Placebo is a normal saline solution (0.9% sodium chloride).</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Severity of Adverse Events.</title>
          <description>Number and severity of adverse events.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with an adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with a severe adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with an adverse event assessed as related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with a serious adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Zika Virus Immune Globulin (ZIKV-IG) Maximum Concentration (Cmax)</title>
        <description>Maximum observed serum concentration of Zika Virus Immune Globulin (ZIKV-IG)</description>
        <time_frame>Up to Day 85</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PK Population ZIKV-IG</title>
            <description>Subjects who received ZIKV-IG with adequate number of PK samples (a suitable pre-dose sample and at least one measurable post-dose sample)</description>
          </group>
          <group group_id="O2">
            <title>PK Population Excluding Subject 01-127 ZIKV-IG</title>
            <description>Subjects who received ZIKV-IG with adequate number of PK samples (a suitable pre-dose sample and at least one measurable post-dose sample) excluding subject 01-127 who likely did not receive the dose intravenously.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Zika Virus Immune Globulin (ZIKV-IG) Maximum Concentration (Cmax)</title>
          <description>Maximum observed serum concentration of Zika Virus Immune Globulin (ZIKV-IG)</description>
          <units>U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.8" spread="0.3"/>
                    <measurement group_id="O2" value="182.3" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Zika Virus Immune Globulin (ZIKV-IG) Time to Maximum Concentration (Tmax)</title>
        <description>Time at which maximum serum concentration of Zika Virus Immune Globulin (ZIKV-IG) occurs.</description>
        <time_frame>Up to Day 85</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PK Population ZIKV-IG</title>
            <description>Subjects who received ZIKV-IG with adequate number of PK samples (a suitable pre-dose sample and at least one measurable post-dose sample)</description>
          </group>
          <group group_id="O2">
            <title>PK Population Excluding Subject 01-127 ZIKV-IG</title>
            <description>Subjects who received ZIKV-IG with adequate number of PK samples (a suitable pre-dose sample and at least one measurable post-dose sample) excluding subject 01-127 who likely did not receive the dose intravenously.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Zika Virus Immune Globulin (ZIKV-IG) Time to Maximum Concentration (Tmax)</title>
          <description>Time at which maximum serum concentration of Zika Virus Immune Globulin (ZIKV-IG) occurs.</description>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="16.4"/>
                    <measurement group_id="O2" value="2.3" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Zika Virus Immune Globulin (ZIKV-IG) Area Under the Curve Up to Last Quantifiable Concentration (AUC0-t)</title>
        <description>Area under the concentration-time curve from time 0 to the last quantifiable serum Zika Virus Immune Globulin (ZIKV-IG) concentration.</description>
        <time_frame>Up to Day 85</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PK Population ZIKV-IG</title>
            <description>Subjects who received ZIKV-IG with adequate number of PK samples (a suitable pre-dose sample and at least one measurable post-dose sample)</description>
          </group>
          <group group_id="O2">
            <title>PK Population Excluding Subject 01-127 ZIKV-IG</title>
            <description>Subjects who received ZIKV-IG with adequate number of PK samples (a suitable pre-dose sample and at least one measurable post-dose sample) excluding subject 01-127 who likely did not receive the dose intravenously.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Zika Virus Immune Globulin (ZIKV-IG) Area Under the Curve Up to Last Quantifiable Concentration (AUC0-t)</title>
          <description>Area under the concentration-time curve from time 0 to the last quantifiable serum Zika Virus Immune Globulin (ZIKV-IG) concentration.</description>
          <units>h*U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66304" spread="0.2"/>
                    <measurement group_id="O2" value="67221" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Zika Virus Immune Globulin (ZIKV-IG) Area Under the Curve Extrapolated to Infinity (AUC0-inf)</title>
        <description>Area under the concentration-time curve from time 0 to the last quantifiable serum Zika Virus Immune Globulin (ZIKV-IG) concentration, plus the area extrapolated to infinity.</description>
        <time_frame>Up to Day 85</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PK Population ZIKV-IG</title>
            <description>Subjects who received ZIKV-IG with adequate number of PK samples (a suitable pre-dose sample and at least one measurable post-dose sample)</description>
          </group>
          <group group_id="O2">
            <title>PK Population Excluding Subject 01-127 ZIKV-IG</title>
            <description>Subjects who received ZIKV-IG with adequate number of PK samples (a suitable pre-dose sample and at least one measurable post-dose sample) excluding subject 01-127 who likely did not receive the dose intravenously.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Zika Virus Immune Globulin (ZIKV-IG) Area Under the Curve Extrapolated to Infinity (AUC0-inf)</title>
          <description>Area under the concentration-time curve from time 0 to the last quantifiable serum Zika Virus Immune Globulin (ZIKV-IG) concentration, plus the area extrapolated to infinity.</description>
          <units>h*U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76170" spread="0.2"/>
                    <measurement group_id="O2" value="77224" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Zika Virus Immune Globulin (ZIKV-IG) Clearance (CL)</title>
        <description>Total body clearance of Zika Virus Immune Globulin (ZIKV-IG) following IV administration.</description>
        <time_frame>Up to Day 85</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PK Population ZIKV-IG</title>
            <description>Subjects who received ZIKV-IG with adequate number of PK samples (a suitable pre-dose sample and at least one measurable post-dose sample)</description>
          </group>
          <group group_id="O2">
            <title>PK Population Excluding Subject 01-127 ZIKV-IG</title>
            <description>Subjects who received ZIKV-IG with adequate number of PK samples (a suitable pre-dose sample and at least one measurable post-dose sample) excluding subject 01-127 who likely did not receive the dose intravenously.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Zika Virus Immune Globulin (ZIKV-IG) Clearance (CL)</title>
          <description>Total body clearance of Zika Virus Immune Globulin (ZIKV-IG) following IV administration.</description>
          <units>mg*mL/h*U</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.061" spread="0.184"/>
                    <measurement group_id="O2" value="0.060" spread="0.179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Zika Virus Immune Globulin (ZIKV-IG) Half-Life (t1/2)</title>
        <description>Apparent first order terminal elimination half-life of Zika Virus Immune Globulin (ZIKV-IG).</description>
        <time_frame>Up to Day 85</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PK Population ZIKV-IG</title>
            <description>Subjects who received ZIKV-IG with adequate number of PK samples (a suitable pre-dose sample and at least one measurable post-dose sample)</description>
          </group>
          <group group_id="O2">
            <title>PK Population Excluding Subject 01-127 ZIKV-IG</title>
            <description>Subjects who received ZIKV-IG with adequate number of PK samples (a suitable pre-dose sample and at least one measurable post-dose sample) excluding subject 01-127 who likely did not receive the dose intravenously.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Zika Virus Immune Globulin (ZIKV-IG) Half-Life (t1/2)</title>
          <description>Apparent first order terminal elimination half-life of Zika Virus Immune Globulin (ZIKV-IG).</description>
          <units>hours</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="674.3" spread="0.2"/>
                    <measurement group_id="O2" value="674.7" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Zika Virus Immune Globulin (ZIKV-IG) Volume of Distribution (Vz)</title>
        <description>Volume of distribution of Zika Virus Immune Globulin (ZIKV-IG) following IV administration.</description>
        <time_frame>Up to Day 85</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PK Population ZIKV-IG</title>
            <description>Subjects who received ZIKV-IG with adequate number of PK samples (a suitable pre-dose sample and at least one measurable post-dose sample)</description>
          </group>
          <group group_id="O2">
            <title>PK Population Excluding Subject 01-127 ZIKV-IG</title>
            <description>Subjects who received ZIKV-IG with adequate number of PK samples (a suitable pre-dose sample and at least one measurable post-dose sample) excluding subject 01-127 who likely did not receive the dose intravenously.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Zika Virus Immune Globulin (ZIKV-IG) Volume of Distribution (Vz)</title>
          <description>Volume of distribution of Zika Virus Immune Globulin (ZIKV-IG) following IV administration.</description>
          <units>mg*mL/U</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.4" spread="0.2"/>
                    <measurement group_id="O2" value="58.6" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from Day 1 (Dosing Day) through Day 85 or early withdrawal.</time_frame>
      <desc>Adverse events were unsolicited.</desc>
      <group_list>
        <group group_id="E1">
          <title>Zika Virus Immune Globulin (ZIKV-IG)</title>
          <description>Single dose of 50 mL Zika Virus Immune Globulin (ZIKV-IG) will be administered intravenously over 33 minutes.
Zika Virus Immune Globulin (ZIKV-IG): Zika Virus Immune Globulin (ZIKV-IG) is a human immune globulin preparation containing neutralizing antibodies to Zika virus.</description>
        </group>
        <group group_id="E2">
          <title>Placebo (Saline Solution)</title>
          <description>Single dose of 50 mL placebo will be administered intravenously over 33 minutes.
Placebo: Placebo is a normal saline solution (0.9% sodium chloride).</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA v21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Tongue pigmentation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Catheter site hypoaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Feeling of body temperature change</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Vessel puncture site bruise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Myoglobin blood increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hypervigilance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>CRO agrees that Emergent shall have the exclusive right to publish the results of each Study under a Task Order, including all Work Product relating thereto, and that such results may not be published or otherwise disseminated by CRO.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jason Richardson, Clinical Research Scientist</name_or_title>
      <organization>Emergent BioSolutions Inc.</organization>
      <phone>204-275-4266</phone>
      <email>jrichardson@ebsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

